The DOI matches its Crossref record.
Phase I study of oxaliplatin in patients with advanced cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Circadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645
Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F., Jasmin, C., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008347829017 · Cited by 606
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Self-citationOxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Alcindor, T., & Beauger, N. (2011) · Current Oncology · doi:10.3747/co.v18i1.708 · Cited by 432
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives
Lee, S. Y., Kim, C. Y., & Nam, T.-G. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s275007 · Cited by 400
de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., André, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., & Krulik, M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00370-x · Cited by 386
Medicine in the Fourth Dimension
Cederroth, C. R., Albrecht, U., Bass, J., Brown, S. A., Dyhrfjeld-Johnsen, J., Gachon, F., Green, C. B., Hastings, M. H., Helfrich-Förster, C., Hogenesch, J. B., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.019 · Cited by 359
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
Hambley, T. W. (1997) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(97)00023-4 · Cited by 348
Gamelin, E., Gamelin, L., Bossi, L., & Quasthoff, S. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35525 · Cited by 321
Bécouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2739 · Cited by 301
Oxaliplatin-related side effects: Characteristics and management
Cassidy, J., & Misset, J.-L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90016-3 · Cited by 298
The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons
Adelsberger, H., Quasthoff, S., Grosskreutz, J., Lepier, A., Eckel, F., & Lersch, C. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00667-1 · Cited by 290
Cabral, H., Nishiyama, N., Okazaki, S., Koyama, H., & Kataoka, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.022 · Cited by 201
Li, C., Pang, Y., Xu, Y., Lu, M., Tu, L., Li, Q., Sharma, A., Guo, Z., Li, X., & Sun, Y. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00227f · Cited by 157
Metadata
- Authors
- Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., & Marty, M.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1990
- Volume
- 25
- Issue
- 4
- Pages
- 299-303
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2052457410
- Cited by
- 343
- References
- 0
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.